Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]
News [2438]
Articles [146]
Editorials [8]
Conferences [102]
elearning [12]
New imaging technique accurately detects aggressive kidney cancer
New imaging technique accurately detects aggressive kidney cancer
Scientist develops new model for ovarian cancer – with crossover to uterine cancer
Scientist develops new model for ovarian cancer – with crossover to uterine cancer
Maybe we shouldn’t even call low-grade prostate cancer “cancer”
Maybe we shouldn’t even call low-grade prostate cancer “cancer”
IMRT and proton therapy offer equally high quality of life and tumour control for people with prostate cancer
IMRT and proton therapy offer equally high quality of life and tumour control for people with prostate cancer
IAEA, Honduras and Japan join forces to strengthen Cancer Care Access through Rays of Hope
IAEA, Honduras and Japan join forces to strengthen Cancer Care Access through Rays of Hope
Inflammatory cells in tumour microenvironment promote the transformation of prostate cancer cells into treatment-resistant cells
Inflammatory cells in tumour microenvironment promote the transformation of prostate cancer cells into treatment...
New prostate biopsy technique lowers infection risk
New prostate biopsy technique lowers infection risk
WCC 2024: Eliminating 5% of all cancers globally could be a reality with today's announcement calling for global gender-neutral HPV vaccination by 2030
WCC 2024: Eliminating 5% of all cancers globally could be a reality with today's announcement calling for global...
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer
ESMO 2024: Alternating pazopanib bevacizumab regimen doubles progression-free survival in metastatic kidney cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation